Physician profile
Jordan Roundtree
NPI 1871286989
$1,796.52
in general payments reported to CMS, 2019-2025
22 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,383 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,769 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.25 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $322.95 | 2024-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $299.38 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $236.30 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $180.84 | 2024-2025 | Auvelity |
| Alkermes, INC. | $104.52 | 2024-2025 | Aristada, Lybalvi |
| Eisai INC. | $88.84 | 2024 | |
| Janssen Pharmaceuticals, INC | $71.74 | 2025 | Spravato |
| Lundbeck LLC | $62.71 | 2024 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $47.27 | 2024 | |
| Amneal Pharmaceuticals LLC | $44.93 | 2024 | Rytary |
| Lilly USA, LLC | $39.48 | 2024 | Emgality, Amyvid |
| Biogen, INC. | $37.81 | 2024 | Vumerity |
| Ucb, INC. | $34.32 | 2024 | Rystiggo |
| Argenx US, INC. | $33.37 | 2024 | Vyvgart Hytrulo |
| Noven Therapeutics, LLC | $32.32 | 2024-2025 | Xelstrym, Secuado |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Almatica Pharma LLC | $26.67 | 2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $23.29 | 2024 | Ingrezza |
| Tris Pharma INC | $22.79 | 2024 | Dyanavel Xr |
| Acadia Pharmaceuticals INC | $22.77 | 2024 | Nuplazid |
| Catalyst Pharmaceuticals, INC. | $19.36 | 2024 | |
| Vanda Pharmaceuticals INC. | $17.59 | 2024 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Roundtree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.